Objective: To study the potential therapeutic effect of Yigan Powder on Alzheimer's disease (AD) comorbid Depressive Disorder with Network Pharmacology. Methods: The active ingredients of Yigan Powder were screened from Traditional Chinese Medicine Systems Pharmacology database and analysis platform (TCMSP) by ADME parameters, targets are predicted by Swiss Target Prediction database, disease targets are downloaded from GeneCards, OMIM and PharGKB database. Using R to run GO terms enrichment and KEGG pathway enrichment analysis. Protein interaction data is downloaded from the String database. Cytoscape software is used to build network. AutoDock Vina and PyMOL software are used for molecular docking. Results: There are 125 active ingredients in Yigan Powder with 953 predicted targets, 85 of predicted targets are related to Alzheimer's Disease comorbid Depressive Disorder, shows highly enriched signaling pathways and biological processes. PPI network shows APP, MAPK1 and STAT3 may be important potential treatment of Alzheimer's Disease comorbid Depressive Disorder. The results of AutoDock Vina docking showed that the active ingredients of Yigan Powder had good binding activity with important receptors. Conclusion: Yigan Powder shows effect on neurotransmitter metabolism, synaptic transmission, neuroinflammation and other aspects in the treatment of Alzheimer's Disease comorbid Depressive Disorder. 相似文献
Lasers in Medical Science - Glioma is the most common primary central nervous system tumor; many methods are currently being used to research and treat glioma. In recent years, fluorescent-guided... 相似文献
Deep brain stimulation (DBS) is a reversible treatment for chorea-acanthocytosis (ChAc). Its safety and efficacy remain elusive due to the low prevalence of ChAc. We aimed to investigate the safety and efficacy of DBS for ChAc by systematically reviewing literature through PubMed and EMBASE. Inclusion criteria were reports on the efficacy or safety of DBS for ChAc and English language articles, and exclusion criteria were other movement disorders, non-human subjects, and studies without original data. Most studies were published as case reports, and we therefore pooled these cases in one cohort. Twenty studies with 34 patients were included. The mean age of symptom onset was 29.3 years (range, 17–48). The median follow-up was 12 months (range, 2–84). Twenty-nine patients underwent GPi-DBS, two received STN-DBS, and one underwent Vop-DBS. Electrodes were implanted into the ventralis oralis complex of the thalamus and the pallidal in two patients. Symptoms seemed to be easier relieved in chorea (88.5%) and dystonia (76.9%) but dysarthria of most patients (85.7%) was no response after DBS. The Unified Huntington’s Disease Rating Scale-Motor Score was used to assess the efficacy of DBS in 25 patients; the mean score decreased from 43.2 to 22.3 and the median improvement rate was 46.7%. Of 24 patients with data on adverse events, complications occurred in 9 patients (37.5%; mostly transient and mild events). DBS is a promising treatment for ChAc with satisfactory efficacy and safety based on the review. Pallidal and thalamic DBS have been applied in ChAc; GPi-DBS seems to be more widely used.
Brain Imaging and Behavior - Impaired capability for understanding and interpreting the expressions on other people's faces manifests itself as a core feature of schizophrenia, contributing to... 相似文献
Cognitive Computation - Low-level features contain abundant details and high-level features have rich semantic information. Integrating multi-scale features in an appropriate way is significant for... 相似文献
Brain Imaging and Behavior - Electroacupuncture (EA) is a safe and effective method for treating obesity. However, how it modulates reward-related brain activity/functional connectivity and gut... 相似文献
Brain Imaging and Behavior - Neuroimaging technique is a powerful tool to characterize the abnormality of brain networks in schizophrenia. However, the neurophysiological substrate of schizophrenia... 相似文献
An ultrasonic-solvent emulsification technique was adopted to prepare vinpocetine loaded Glyceryl monostearate (GMS) nanodispersions with narrow size distribution. To increase the lipid load the process was conducted at 50 degrees C, and in order to prepare nanoparticle using an ultrasonic-solvent emulsification technique. The mean particle size and droplet size distribution, drug loading capacity, drug entrapment efficiency (EE%), zeta potential, and long-term physical stability of the SLNs were investigated in detail respectively. Drug release from two sorts of VIN-SLN was studied using a dialysis bag method. A pharmacokinetic study was conducted in male rats after oral administration of 10 mg kg(-1) VIN in different formulations, it was found that the relative bioavailability of VIN in SLNs was significantly increased compared with that of the VIN solution. The amount of surfactant also had a marked effect on the oral absorption of VIN with SLN formulations. The absorption mechanism of the SLN formulations was also discussed. These results indicated that VIN absorption is enhanced significantly by employing SLN formulations. SLNs offer a new approach to improve the oral bioavailability of poorly soluble drugs. 相似文献